NRG
CRSP icon

Nemes Rush Group’s CRISPR Therapeutics CRSP Stock Holding History

Nemes Rush Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-85
Closed -$5.79K – 745
2024
Q3 		$5.79K Hold
85
– – ﹤0.01% 452
2024
Q2 		$4.59K Hold
85
– – ﹤0.01% 470
2024
Q1 		$5.79K Hold
85
– – ﹤0.01% 488
2023
Q4 		$5.32K Hold
85
– – ﹤0.01% 480
2023
Q3 		$3.86K Sell
85
-1,831
-96% -$94.6K ﹤0.01% 496
2023
Q2 		$108K Buy
+1,916
New +$109K 0.02% 208

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nemes Rush Group's CRSP Position: Q4 2024 in Review

Nemes Rush Group sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 85 shares — an estimated $5.79K sold.

Nemes Rush Group first reported a position in CRSP in Q2 2023 and held it in 6 quarters. The position peaked at $108K in Q2 2023. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Nemes Rush Group reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nemes Rush Group sold 85 CRISPR Therapeutics shares in Q4 2024, an estimated $5.79K.
  • Nemes Rush Group first reported a position in CRISPR Therapeutics in Q2 2023 and held it in 6 quarters.
  • Nemes Rush Group's CRISPR Therapeutics position peaked at $108K in Q2 2023.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Nemes Rush Group's 13F filing for Q4 2024, filed 12 Feb 2025.